Based on Recent FDA Feedback RAPT Therapeutics Stops Zelnecirnon Program Following Clinical Hold Due to Single SAE of Severe Liver Injury


Continues to advance preclinical pipeline, including next generation CCR4 compounds, and pursue licensing opportunities Continues to advance preclinical pipeline, including next generation CCR4 compounds, and pursue licensing opportunities

Read more:
Based on Recent FDA Feedback RAPT Therapeutics Stops Zelnecirnon Program Following Clinical Hold Due to Single SAE of Severe Liver Injury

Related Posts